Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Fr Anesth Reanim ; 32(1): 25-30, 2013 Jan.
Article in French | MEDLINE | ID: mdl-23260628

ABSTRACT

OBJECTIVES: The efficacy of single-dose intraincisional infiltration with levobupivacaine in postoperative analgesia and chronic pain after caesarean sections is unknown. STUDY: A placebo-controlled double-blind randomized trial. PATIENTS AND METHODS: After ethical approval, and written inform consent, 140 women scheduled for a caesarean section were randomly assigned and received 30mL of levobupivacaine 0.5% (L group) or saline (placebo-P group) into their wound. The primary endpoint was morphine consumption (using intravenous morphine patient-controlled analgesia) for the first 24h after surgery. At 1h to 48h, side effects, pain at rest and pain 2months later were recorded. RESULTS: All included patients had similar demographic and surgical characteristics. The morphine consumption was significantly lower in the L group at h6, h8 and h12 (considering both total intake and each request). At h4, the mean total morphine consumption was 25 (12) mg in the L group versus 31 (14) mg in the P group (P=0.05). Time until discharge and side effects including nausea-vomiting (14 vs 20%), wound scar complications (6 vs 8%) and chronic pain after 2months (25% in both groups complained of small pain, and 75% no pain) were similar between the two groups (P>0.05). CONCLUSION: Single-dose local infiltration of levobupivacaine 0.5% reduced opioid requirement at 12h, with no difference after 24h. www.clinicaltrials.com, number: NCT00621907.


Subject(s)
Anesthetics, Local/therapeutic use , Cesarean Section , Pain, Postoperative/drug therapy , Adult , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/therapeutic use , Anesthetics, Local/administration & dosage , Bupivacaine/administration & dosage , Bupivacaine/analogs & derivatives , Bupivacaine/therapeutic use , Double-Blind Method , Endpoint Determination , Female , Humans , Infant, Newborn , Levobupivacaine , Morphine/administration & dosage , Morphine/therapeutic use , Pain Measurement , Parity , Postoperative Nausea and Vomiting/epidemiology , Pregnancy
2.
Ann Fr Anesth Reanim ; 29(1): 55-7, 2010 Jan.
Article in French | MEDLINE | ID: mdl-20074899

ABSTRACT

INTRODUCTION: As the susceptibility of staphylococcal strains to glycopeptides rises, it is becoming necessary to increase vancomycin dosages. OBJECTIVE: To evaluate an administration protocol for vancomycin using continuous infusion with a loading dose of 30 mg/kg followed by 30 mg/kg per 24h in intensive care patients presenting creatinine clearance (CLc) greater than 50. RESULTS: A total of 22 patients were included in the study. Serum vancomycin concentrations after 24h (C24h) ranged from 25 to 30 mg/l in seven of 14 patients with CLc less than 120 ml/min (50 %), compared with three patients (21 %) with C24h greater than 35 mg/l and four patients (29 %) with C24 h less than 25 mg/l. However, C24h was less than 20mg/l for the eight patients with CLc greater or equal to 120 ml/min. Bacteriological data was available for eight of the 14 patients with CLc less than 120 ml/min, and in these eight patients, the C24h/MIC was greater or equal to 8; seven of these patients had an AUC/MIC greater or equal to 350. CONCLUSION: Assay of serum vancomycin concentrations after 24h of treatment is necessary to enable rapid adjustment of vancomycin concentration in order to improve therapeutic efficacy or avoid nephrotoxicity.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Critical Care/methods , Critical Illness , Methicillin-Resistant Staphylococcus aureus/drug effects , Vancomycin/administration & dosage , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/therapeutic use , Clinical Protocols , Cross Infection/drug therapy , Cross Infection/microbiology , Cross Infection/prevention & control , Dose-Response Relationship, Drug , Drug Monitoring , Hospitals, University , Humans , Infusions, Intravenous , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Recovery Room , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcal Infections/prevention & control , Staphylococcus epidermidis/drug effects , Staphylococcus epidermidis/isolation & purification , Staphylococcus haemolyticus/drug effects , Staphylococcus haemolyticus/isolation & purification , Vancomycin/blood , Vancomycin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...